These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23089348)

  • 1. Emerging therapies: what's new is old and what's old is new.
    Barkin J; Folia C
    Can J Urol; 2012 Oct; 19 Suppl 1():49-53. PubMed ID: 23089348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
    Liu XS; Folia C; Gomella LG
    Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
    Andersson KE; de Groat WC; McVary KT; Lue TF; Maggi M; Roehrborn CG; Wyndaele JJ; Melby T; Viktrup L
    Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific pharmacokinetic aspects of the urinary tract.
    Korstanje C; Krauwinkel W
    Handb Exp Pharmacol; 2011; (202):267-82. PubMed ID: 21290231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
    Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
    BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign prostatic hyperplasia (BPH) management in the primary care setting.
    Kapoor A
    Can J Urol; 2012 Oct; 19 Suppl 1():10-7. PubMed ID: 23089343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uropharmacology for the primary care physician.
    Gittens PR; Lallas CD; Pe ML; Perkel R; Folia C; Gomella LG
    Can J Urol; 2008 Aug; 15 Suppl 1():78-91; discussion 91. PubMed ID: 18700069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uropharmacology in primary care: 2010 update.
    Gomella LG; Lallas CD; Perkel R; Folia C; Hirsch I; Das A; Shenot P
    Can J Urol; 2010 Feb; 17 Suppl 1():35-51. PubMed ID: 20170599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of anticholinergic drugs in men with lower urinary tract symptoms.
    Armitage J; Emberton M
    Curr Opin Urol; 2008 Jan; 18(1):11-5. PubMed ID: 18090483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum neurotoxin A for male lower urinary tract symptoms.
    Chartier-Kastler E; Mehnert U; Denys P; Giuliano F
    Curr Opin Urol; 2011 Jan; 21(1):13-21. PubMed ID: 21099691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.
    Rosen RC; Seftel AD
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S27-32. PubMed ID: 19002122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Blockers for benign prostatic hyperplasia: the new era.
    Lepor H; Kazzazi A; Djavan B
    Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.